Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080597826> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W3080597826 endingPage "2013" @default.
- W3080597826 startingPage "2009" @default.
- W3080597826 abstract "Thirty-nine (39) new drugs have been approved by the U.S. FDA in 2012, a record highest number of approvals since 1996. The record is a sign that pharma companies are poised to tap recent advances from genomics and proteomics. This list includes novel new drugs, known as new molecular entities (NMEs), biologics and new products. Many life-saving drugs are approved for marketing. The list includes a total of 10 drugs for cancer treatment, and nearly a quarter of those approved in 2012 had orphan drug status. Among the breakthrough drugs approved in 2012 were ivacaftor (cystic fibrosis), vasmodegib (skin cancer), HPC-C (human cord blood product), ruxolitinib (myelofibrosis) and a new combination drug to treat HIV. In addition, several unique products were approved for the treatment of macular degeneration, chronic weight management, overactive bladder, actinic keratosis, erectile dysfunction, glaucoma, respiratory distress syndrome, and COPD. The approval of 39 drugs in 2012 underscores a robust success rate and confirms that innovation is once again beginning to pay off. In the existing climate of reduced revenues in the face of generic competitions, the future and survival of big companies rests heavily on their unique niche products. It is apparent that big Pharma and a growing number of emerging Biotechs alike have focused their attention on developing new NMEs for rare diseases. In 2012, the length of the FDA’s review is shorter than agencies in other countries. Innovative models adopted for R&D strategies, communications, and new regulatory changes appear to shorten development timelines. Despite record drug approvals, there is bleak scope for blockbusters because most of these drugs have a limited market. The pipeline for blockbusters appears very low. However, there is unmet medical need for new drugs in autism, Alzheimer’s disease and epilepsy. Overall, the new drug approval list unveils unique and reemerging trends indicating that the pharma companies are poised for big growth from new brands approved for marketing for narrow-spectrum indications. 
" @default.
- W3080597826 created "2020-09-01" @default.
- W3080597826 creator A5006446144 @default.
- W3080597826 date "2013-08-31" @default.
- W3080597826 modified "2023-09-26" @default.
- W3080597826 title "New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States" @default.
- W3080597826 cites W2011793809 @default.
- W3080597826 cites W2028279608 @default.
- W3080597826 cites W2043099237 @default.
- W3080597826 cites W2052214665 @default.
- W3080597826 cites W2062873043 @default.
- W3080597826 cites W2089265290 @default.
- W3080597826 cites W3080136470 @default.
- W3080597826 doi "https://doi.org/10.37285/ijpsn.2013.6.2.1" @default.
- W3080597826 hasPublicationYear "2013" @default.
- W3080597826 type Work @default.
- W3080597826 sameAs 3080597826 @default.
- W3080597826 citedByCount "3" @default.
- W3080597826 countsByYear W30805978262014 @default.
- W3080597826 crossrefType "journal-article" @default.
- W3080597826 hasAuthorship W3080597826A5006446144 @default.
- W3080597826 hasConcept C126322002 @default.
- W3080597826 hasConcept C512399662 @default.
- W3080597826 hasConcept C59491497 @default.
- W3080597826 hasConcept C60644358 @default.
- W3080597826 hasConcept C71924100 @default.
- W3080597826 hasConcept C75480439 @default.
- W3080597826 hasConcept C86803240 @default.
- W3080597826 hasConceptScore W3080597826C126322002 @default.
- W3080597826 hasConceptScore W3080597826C512399662 @default.
- W3080597826 hasConceptScore W3080597826C59491497 @default.
- W3080597826 hasConceptScore W3080597826C60644358 @default.
- W3080597826 hasConceptScore W3080597826C71924100 @default.
- W3080597826 hasConceptScore W3080597826C75480439 @default.
- W3080597826 hasConceptScore W3080597826C86803240 @default.
- W3080597826 hasIssue "2" @default.
- W3080597826 hasLocation W30805978261 @default.
- W3080597826 hasOpenAccess W3080597826 @default.
- W3080597826 hasPrimaryLocation W30805978261 @default.
- W3080597826 hasRelatedWork W2332686213 @default.
- W3080597826 hasRelatedWork W2521155991 @default.
- W3080597826 hasRelatedWork W2913956994 @default.
- W3080597826 hasRelatedWork W2936507319 @default.
- W3080597826 hasRelatedWork W2978947188 @default.
- W3080597826 hasRelatedWork W3034425396 @default.
- W3080597826 hasRelatedWork W3129479980 @default.
- W3080597826 hasRelatedWork W3214063588 @default.
- W3080597826 hasRelatedWork W4205735302 @default.
- W3080597826 hasRelatedWork W4225794805 @default.
- W3080597826 hasVolume "6" @default.
- W3080597826 isParatext "false" @default.
- W3080597826 isRetracted "false" @default.
- W3080597826 magId "3080597826" @default.
- W3080597826 workType "article" @default.